Aristotle University Of Thessaloniki (AUTH)
Διαχρονική μελέτη των προτύπων θεραπείας και της εμφάνισης των δεύτερων κακοηθειών σε ασθενείς με χρόνια λεμφοκυτταρική λευχαιμία
Abstract
dc:descriptionChronic Lymphocytic Leukemia (CLL) is the most common hematologic malignancy in the Western world. Even though many retrospective studies report an increased incidence of other malignancies (OM), the precise association of their occurrence with the clinical and biological features of CLL and/or CLL treatment remains unknown. Immunosuppression and CLL treatment could explain the increased incidence of second malignancies, although this theory has not been proven. Moreover, in the past decade, a better understanding of disease biology and the advent of targeted therapies have radically changed CLL management. However, critical questions regarding the optimal sequencing of treatments with targeted agents are still unknown. The aim of this study was (i) to characterize the occurrence of OM in a population of patients with CLL, (ii) to evaluate the overall survival (OS) of patients with CLL and OM, (iii) to identify potential risk factors for OMs, (iv) to describe the treatment sequence patterns in the 'real world' in the era of chemoimmunotherapy; and (v) to describe the outcomes of patients with relapsed or refractory CLL (RR CLL) who received targeted agents. This study consists of two international multicentric retrospective observational studies conducted by ERIC, the European Research Initiative on CLL. In the first study, investigators from each center provided data on (i) consecutive patients diagnosed with CLL between 2000-2016 (first study) and (ii) consecutive patients treated for CLL between 2000-2016 (second study). We evaluated data from 19,705 patients with CLL from 85 different centers in 28 countries. Overall, 16.6% developed at least one OM after diagnosis of CLL (27.2 new OMs per 1,000 person-years). The most common hematological OMs were Richter syndrome, myelodysplastic syndrome (MDS), and acute myeloid leukemia (AML). Non-melanoma skin cancers and prostate cancer were the most frequent solid tumors. Patients with OM had worse OS compared to patients who did not develop OM. AML and MDS conferred the worst OS (p < 0.001). The only predictor for MDS and AML development was treatment with fludarabine and cyclophosphamide with/without rituximab (FC ± R) (OR = 3.7; 95% CI = 2.79-4.91; p < 0.001). In the second study, we analyzed data from 7,382 patients who had received at least one line of treatment for CLL from 76 centers in 25 countries. An increase in the use of targeted agents and a decrease in the use of chemo(immuno)therapy was evident in patients treated after 2014 compared to before. Increased age, unmutated IGHV genes, and TP53 aberrations were the only statistically significant factors associated with worse OS in patients with RR CLL. The only protective factor against death was treatment with targeted agents in the first or second line (HR: 0.58, 95% CI: 0.45-0.76). OMs in CLL negatively impact OS. FCR was associated with an increased risk for AML/MDS. Finally, incorporating new agents early in the CLL treatment algorithm improved outcomes in patients with RR CLL.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Chatzikonstantinou, Thomas
- Χατζηκωνσταντίνου, Θωμάς
Subjects
dc:subject × 14Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/59183